Cellectis vs Monte Rosa Therapeutics
CLLS and GLUE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLLS and GLUE compare
Cellectis grew revenue faster over the last twelve months (75.8% versus −61.3% for Monte Rosa Therapeutics).
Cellectis keeps more of each dollar of sales as profit, with a net margin of −92.7% compared with −186% at Monte Rosa Therapeutics.
Monte Rosa Therapeutics scores higher on the StockData Score (7 against 3 for Cellectis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLLS | GLUE |
|---|---|---|
| Size and price | ||
| Market cap | – | $799M |
| Share price | $1.18 | $9.37 |
| Change, 1 year | −67.7% | −33.8% |
| Change, 5 years | −86.8% | −52.1% |
| Beta (5Y) | 2.07 | 1.83 |
| Employees | 229 | 150 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 11.4× |
| P/B | – | 1.6× |
| FCF yield | – | −21.8% |
| Fair value | – | $8.37 |
| Margin of safety | – | −11.9% |
| Growth | ||
| Revenue growth (TTM) | 75.8% (better) | −61.3% |
| Revenue growth, 5Y average | 7.4% | – |
| Net income growth (TTM) | – | −725% |
| EPS growth (TTM) | – | −660% |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | −45.3% (better) | −214% |
| Net margin | −92.7% (better) | −186% |
| FCF margin | −57.2% (better) | −248% |
| Return on equity | −97.8% | −35.3% (better) |
| Return on invested capital | −122% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.6× | – |
| Current ratio | – | 10.32 |
| Altman Z-score | – | 1.63 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 9.4% | 109% |
| Held by insiders | 53.4% | 11.5% |
| Insider net buying, 12 months | – | −$4.1M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 27.6% |
Go deeper
- CLLS stock overview
- CLLS income statement
- CLLS valuation and score
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.